Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129019) titled 'An Exploratory Clinical Trial Evaluating the Safety and Efficacy of Rimegepant in Combination With Toripalimab for Advanced Urothelial Carcinoma After Failure of Standard Therapy' on July 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Condition:
Advanced Urothelial Carcinoma After Failure of Standard Therapy
Intervention:
Dose Level 2:All patients received Remimazolam (75mg, qd) combined with Toripalimab treatment and completed the 14-day DLT observation period.
Recruitment Status: Not Recr...